Taiwan Biomaterial Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023
Share
Taiwan Biomaterial Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 9.28 million compared to TWD 40.97 million a year ago. Net loss was TWD 8.3 million compared to net income of TWD 19.29 million a year ago. Basic loss per share from continuing operations was TWD 0.2 compared to basic earnings per share from continuing operations of TWD 0.46 a year ago. Diluted loss per share from continuing operations was TWD 0.2 compared to diluted earnings per share from continuing operations of TWD 0.46 a year ago.
For the nine months, sales was TWD 56.6 million compared to TWD 81.37 million a year ago. Net loss was TWD 2.67 million compared to net income of TWD 18.01 million a year ago. Basic loss per share from continuing operations was TWD 0.06 compared to basic earnings per share from continuing operations of TWD 0.44 a year ago. Diluted loss per share from continuing operations was TWD 0.06 compared to diluted earnings per share from continuing operations of TWD 0.44 a year ago.
Taiwan Biomaterial Co., Ltd. is a Taiwan-based company mainly engaged in provision of medical equipment. The products are still in research and development stage. The Company's subsidiary TAIWAN MEDICAL RAPID PROTOTYPING CO., LTD.(TRP) is engaged in trial production of medical equipment. Main products include foam artificial meninges products, stroke thrombus aspiration catheter products, repair and regeneration products for early degenerative arthritis and others.